<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942021000400358</article-id>
<article-id pub-id-type="doi">10.30827/ars.v62i4.21029</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Comparison of in vitro, in vivo, and in silico bioavailability results of different prednisone tablet formulations to assess the feasibility of possible biowaiver]]></article-title>
<article-title xml:lang="es"><![CDATA[Comparación de los resultados de biodisponibilidad in vitro, in vivo e in silico de diferentes formulaciones de comprimidos de prednisona para evaluar la viabilidad de una posible bioexención]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Toehwé]]></surname>
<given-names><![CDATA[Leonardo Henrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[da Silva Honorio]]></surname>
<given-names><![CDATA[Thiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues Pereira da Silva]]></surname>
<given-names><![CDATA[Luiz Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martins da Silva]]></surname>
<given-names><![CDATA[Thalita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[da Rocha Pitta]]></surname>
<given-names><![CDATA[Luciana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[Livia Deris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendes Cabral]]></surname>
<given-names><![CDATA[Lucio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Antunes Rocha]]></surname>
<given-names><![CDATA[Helvécio Vinícius]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fiocruz Programa de Pós-graduação Profissional em Gestão, Pesquisa e Desenvolvimento na Indústria Farmacêutica. Farmanguinhos ]]></institution>
<addr-line><![CDATA[Rio de Janeiro ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Federal do Rio de Janeiro Faculdade de Farmácia Laboratório de Tecnologia Industrial Farmacêutica, Departamento de Fármacos e Medicamentos]]></institution>
<addr-line><![CDATA[Rio de Janeiro ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade Federal do Rio de Janeiro Faculdade de Farmácia Laboratório de Nanoteranósticos, Departamento de Fármacos e Medicamentos]]></institution>
<addr-line><![CDATA[Rio de Janeiro ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Farmanguinhos. Fiocruz Laboratório de Micro e Nanotecnologia ]]></institution>
<addr-line><![CDATA[Rio de Janeiro ]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>62</volume>
<numero>4</numero>
<fpage>358</fpage>
<lpage>370</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942021000400358&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942021000400358&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942021000400358&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The immediate-release solid oral products containing very soluble and permeable drugs are candidates for the biowaiver process. This work aims to compare in vitro, in silico, and in vivo data to establish if previously published prednisone oral tablet formulations are biowaiver candidates.  Method:  To achieve this goal, permeation studies were conducted on Caco-2 cells. A previous bioequivalence study between the test and the reference drug product was applied on an in silico evaluation using Gastroplus® to assess the bioequivalence of two other previously proposed formulations.  Results:  The apparent permeability coefficient for prednisone presented a value of 3.69 x 10-5 cm/s in 180 minutes. The bioequivalence study shows that the tested and reference product was equivalent. The in silico simulations successfully predicted the pharmacokinetics of the tested and the other two formulations since they were validated with the in vivo study. Both exhibit the same plasma concentration vs. time profiles.  Conclusions: Through the in silico results, it is possible to infer that the other two formulations tested may be bioequivalent concerning the reference product. This result may be helpful in biowaiver requesting. Toward to reduce costs and the use of human beings in bioequivalence studies, this approach could be an essential way to work in the pharmaceutical industry.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Los productos orales sólidos de liberación inmediata que contienen fármacos muy solubles y permeables son candidatos para el proceso de bioexención. Este trabajo tiene como objetivo comparar datos in vitro, in silico e in vivo para establecer si las formulaciones de comprimidos orales de prednisona publicadas anteriormente son candidatas a la bioexención.  Método:  Para lograr este objetivo se realizaron estudios de permeación en células Caco-2. Se aplicó un estudio de bioequivalencia previo entre la formulación de prueba y el medicamento de referencia en una evaluación in silico utilizando Gastroplus® para evaluar la bioequivalencia de otras dos formulaciones propuestas anteriormente.  Resultados: El coeficiente de permeabilidad aparente para prednisona presentó un valor de 3,69 x 10-5 cm/s en 180 minutos. El estudio de bioequivalencia muestra que el producto probado y de referencia era equivalente. Las simulaciones in silico predijeron con éxito la farmacocinética de las formulaciones probadas y las otras dos, ya que fueron validadas con el estudio  in vivo . Ambos exhiben los mismos perfiles de concentración plasmática frente a tiempo.  Conclusiones:  A través de los resultados  in silico , es posible inferir que las otras dos formulaciones ensayadas pueden ser bioequivalentes respecto al producto de referencia. Este resultado puede ser útil en la solicitud de bioexenciones. Para reducir los costos y el uso de seres humanos en los estudios de bioequivalencia, este enfoque podría ser una forma esencial de trabajar en la industria farmacéutica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[prednisona]]></kwd>
<kwd lng="es"><![CDATA[simulación in silico]]></kwd>
<kwd lng="es"><![CDATA[biodisponibilidad]]></kwd>
<kwd lng="es"><![CDATA[bioexención]]></kwd>
<kwd lng="en"><![CDATA[prednisone]]></kwd>
<kwd lng="en"><![CDATA[in silico simulation]]></kwd>
<kwd lng="en"><![CDATA[bioavailability]]></kwd>
<kwd lng="en"><![CDATA[biowaiver]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>FDA. Food and Drug Administration</collab>
<source><![CDATA[Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs-General Considerations]]></source>
<year>2014</year>
<publisher-name><![CDATA[U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Derendorf]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Junginger]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Midha]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: prednisone]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>2007</year>
<volume>96</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1480-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<source><![CDATA[Lista de medicamentos de referência]]></source>
<year>2020</year>
<page-range>54</page-range><publisher-loc><![CDATA[Brasília ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>BRASIL. Ministério da Saúde. Agência Nacional de Vigilância Sanitária</collab>
<article-title xml:lang=""><![CDATA[Resolução de Diretoria Colegiada no 37, de 3 de agosto de 2011. Dispõe sobre o guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2011</year>
<numero>150</numero>
<issue>150</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Storpirtis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Chiann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gai]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
</person-group>
<source><![CDATA[Ciências farmacêuticas: biofarmacotécnica]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Rio de Janeiro, Brazil ]]></publisher-loc>
<publisher-name><![CDATA[Guanabra Koogan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waterbeend]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Testa]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioavailability: estimation of solubility, permeability, absorption and bioavailability]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Dusseldorf ]]></publisher-loc>
<publisher-name><![CDATA[Wiley-UCH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Löbenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biorelevant dissolution media as a predictive tool for glyburide a class II drug]]></article-title>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2006</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okumu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DiMaso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Löbenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Computer simulations using GastroPlus(r) to justify a biowaiver for etoricoxib solid oral drug products]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2009</year>
<volume>72</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>BRASIL. Ministério da Saúde. Agência Nacional de Vigilância Sanitária</collab>
<article-title xml:lang=""><![CDATA[Instrução Normativa n. 2, de 14 de março de 2013. Determina a publicação da lista de fármacos candidatos à bioisenção baseada no sistema de classificação biofarmacêutica]]></article-title>
<source><![CDATA[Diário Oficial da União]]></source>
<year>2013</year>
<numero>51</numero>
<issue>51</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toehwé]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[HVA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prednisone raw material characterization and formulation development]]></article-title>
<source><![CDATA[Braz J Pharm Sci]]></source>
<year>2018</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Annaert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gelder]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Naesems]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[De Clercq]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mooter]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kinget]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carrier mechanisms invelved in the transephitelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>1998</year>
<volume>15</volume>
<page-range>1168-73</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonferoni]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Finotelli]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity]]></article-title>
<source><![CDATA[Int J Nanomedicine]]></source>
<year>2012</year>
<volume>7</volume>
<page-range>2975</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Konsoula]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barile]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells]]></article-title>
<source><![CDATA[Toxicol In vitro]]></source>
<year>2005</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>675-84</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonferoni]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Boselli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caramella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin-Loaded Nanoparticles Based on N-Trimethyl Chitosan: In vitro (Caco-2 Model) and Ex Vivo (Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2010</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>362-71</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonferoni]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gibin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zambito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2007</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-77</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Youdim]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Avdeef]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abbott]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro trans-monolayer permeability calculations: often forgotten assumptions]]></article-title>
<source><![CDATA[Drug Discov Today]]></source>
<year>2003</year>
<volume>8</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>997-1003</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Nucleo de Bioequivalência e Ensaios Clínicos. Universidade Federal de São Paulo</collab>
<source><![CDATA[Relatório final do estudo de biodisponibilidade relativa de prednisona 20 mg]]></source>
<year>2011</year>
<publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Honório T da]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[HVA]]></given-names>
</name>
<name>
<surname><![CDATA[Esteves]]></surname>
<given-names><![CDATA[VSD]]></given-names>
</name>
<name>
<surname><![CDATA[dos Santos]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[HCR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro-In vivo Correlation of Efavirenz Tablets Using GastroPlus(r)]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2013</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1244-54</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Simulation Plus</collab>
<source><![CDATA[GastroPlus(r) 9.1 User Manual]]></source>
<year>2017</year>
<page-range>696</page-range><publisher-loc><![CDATA[Lancaster ]]></publisher-loc>
<publisher-name><![CDATA[California]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grbic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Parojcic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ibric]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Djuric]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro-In vivo Correlation for Gliclazide Immediate-Release Tablets Based on Mechanistic Absorption Simulation]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2011</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>165-71</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duque]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Issa]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Löbenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraz]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2019</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>BRASIL. Ministério da Saúde. Agência Nacional de Vigilância Sanitária</collab>
<source><![CDATA[Resolução - RE n. 1170, de 19 de abril de 2006. Determina a publicação do Guia para Provas de Biodisponibilidade Relativa/Bioequivalência de Medicamentos]]></source>
<year>2006</year>
<page-range>8</page-range><publisher-loc><![CDATA[Brasilia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Furubayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kataoka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sakane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sezaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tokuda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells]]></article-title>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2000</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>195-204</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Wibowo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[KQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical Salt Formation Guided by Phase Diagrams]]></article-title>
<source><![CDATA[Ind Eng Chem Res]]></source>
<year>2010</year>
<volume>49</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>12503-12</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bock]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kottke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gindorf]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haltner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Validation of the Caco-2 cell monolayer system for determining the permeability of drug substances according to the Biopharmaceutical Classification System (BCS)]]></source>
<year>2003</year>
<page-range>1-7</page-range><publisher-loc><![CDATA[Saarbrucken ]]></publisher-loc>
<publisher-name><![CDATA[Across Barriers]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tubic-Grozdanis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bolger]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Langguth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds]]></article-title>
<source><![CDATA[AAPS J]]></source>
<year>2008</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>213-26</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosembaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basic Pharmacokinetics and Pharmacodynamics: an integrated textbook and computer simulations]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rosembaum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Compartmental Models in Pharmacokinetics]]></source>
<year>2017</year>
<page-range>145-57</page-range><publisher-loc><![CDATA[Hoboken, NJ ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley &amp; Sons, Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tozer]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introdução à Farmacocinética e à Farmacodinâmica: as bases quantitativas da terapia farmacológica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Tozer]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacocinética e Farmacodinâmica]]></source>
<year>2009</year>
<page-range>2-25</page-range><publisher-loc><![CDATA[Porto Alegre ]]></publisher-loc>
<publisher-name><![CDATA[Artmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<collab>U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)</collab>
<source><![CDATA[Guidance for Industry to Dissolution Testing for Immediate Release Solid Oral Dosage Forms. U.S]]></source>
<year>1997</year>
<publisher-loc><![CDATA[Government Printing Office ]]></publisher-loc>
<publisher-name><![CDATA[Washington, DC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emami]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro-in vivo correlation: From theory to applications]]></article-title>
<source><![CDATA[J Pharm Pharm Sci]]></source>
<year>2006</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>31-51</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Tabakha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fahelelbom]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Obaid]]></surname>
<given-names><![CDATA[DEE]]></given-names>
</name>
<name>
<surname><![CDATA[Sayed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality Attributes and In vitro Bioequivalence of Different Brands of Amoxicillin Trihydrate Tablets]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2017</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
